Beacon NewsFlashes – October 22, 2012
Published: Oct 22, 2012 2:09 pm
Sapacitabine May Extend Survival For Elderly MDS Patients – Cyclacel Pharmaceuticals (NASDAQ: CYCC) recently announced intermediate results from an ongoing Phase 2 clinical trial of its investigational drug sapacitabine (CYC682). In this study, elderly higher-risk myelodysplastic syndromes (MDS) patients who had previously failed Vidaza (azacitidine) or Dacogen (decitabine) treatment were treated with sapacitabine using one of three dosing schedules. Patients from all three dosing groups survived for a median of 8.2 months. Those patients with at least 10 percent immature bone marrow cells had a median survival of 9 months. Survival for higher-risk patients is typically about 5 months. For more information, please see the Cyclacel press release or the clinical trial description.
Phase 2 Study To Investigate Treatment For Skin Thickening Due To Chronic Graft-Versus-Host Disease – A Phase 2 study comparing Rituxan (rituximab) and Gleevec (imatinib) for the treatment of skin thickening due to chronic graft-versus-host disease is currently recruiting participants. Graft-versus-host disease is a common side effect of donor (also known as allogeneic) stem cell transplantation. It occurs when the donor bone marrow stem cells recognize the recipient’s cells as foreign and attack them. The trial is taking place at seven treatment centers throughout the United States and is enrolling patients who were diagnosed in the last 12 months with skin thickening after receiving a stem cell transplant. For more information, please see the clinical trial description.
Webinar On Clinical Trials For MDS Patients And Family – The Aplastic Anemia & MDS International Foundation (AA&MDSIF) will host a free webinar on October 25 at 3 p.m. Eastern Time. Oncology nurses from the University of Minnesota, Melinda Baxter and Pat Fidler, will discuss clinical trials and what patients with bone marrow failure should know about clinical trial participation. For more information or to register, please see the event description at the AA&MDSIF website.